V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005257 | 10003279 | 1.6 | 57.38 | Palliative (P) | 2019-06-12 | 2019-06-12 | BORTEZOMIB + THALIDOMIDE | 2 | N | 10372973 | NIVOLUMAB |
| 10005258 | 10003279 | 1.79 | 68.9 | Palliative (P) | 2016-12-24 | 2017-01-20 | Bevacizumab 5mg/kg | N | N | 10372973 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005259 | 10003280 | 1.75 | 72 | Palliative (P) | null | 2019-01-14 | Alemtuzumab | N | N | 10374253 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10005260 | 10003281 | 1.74 | 60.6 | Palliative (P) | 2017-11-30 | 2017-12-11 | AML18 PILOT TRIAL | 2 | N | 10374278 | TEMOZOLOMIDE |
| 10005261 | 10006829 | 1.83 | 73 | null | 2015-05-21 | 2015-07-02 | FCR | N | Y | 10376328 | AFATINIB |
| 10005262 | 10003282 | 1.57 | 0 | Palliative (P) | 2016-12-11 | 2016-12-11 | IBRUTINIB | N | N | 10376975 | PAZOPANIB |
| 10005263 | 10003283 | 0 | 50.8 | Curative (C) | 2018-01-30 | 2018-02-23 | Cytarabine HD + Methotrexate HD | N | Y | 10377873 | MITOMYCIN |
| 10005264 | 10003284 | 1.77 | 83 | null | 2015-02-04 | 2015-02-17 | Erlotinib | Y | N | 10378607 | PILOT TRIAL |
| 10005265 | 10003285 | null | 74 | Palliative (P) | 2017-10-29 | 2017-10-29 | Trastuzumab Subcutaneous | 02 | N | 10378615 | FLUOROURACIL + RT |
| 10005266 | 10003286 | 1.48 | 77.8 | null | 2014-09-28 | 2014-10-06 | Folfirinox | N | N | 10378628 | DOCETAXEL + GEMCITABINE |
| 10005267 | 10003287 | null | 85 | Palliative (P) | 2018-06-05 | 2018-06-24 | AML18 PILOT TRIAL | N | Y | 10379036 | VEMURAFENIB |
| 10005268 | 10003288 | 1.65 | 55.3 | Palliative (P) | 2019-02-20 | 2019-02-20 | Cisplatin +Fluorouracil (2 wk) | 02 | N | 10379193 | GEFITINIB |
| 10005269 | 10003288 | 1.86 | 67.5 | null | 2017-02-01 | 2017-02-04 | VINCRISTINE | 2 | N | 10379193 | IPILIMUMAB |
| 10005270 | 10003289 | null | 45 | Disease modification (D) | 2017-12-29 | 2018-01-12 | Doxorubicin + Ifosfamide | N | N | 10381674 | MELPHALAN |
| 10005271 | 10003290 | 1.7 | 82.1 | Adjuvant (A) | 2019-01-15 | 2019-02-20 | Ipilimumab | N | N | 10382210 | INCA TRIAL |
| 10005272 | 10003290 | 1.63 | 87.6 | Curative (C) | 2019-07-21 | 2019-07-27 | VEDex | N | N | 10382210 | VISMODEGIB |
| 10005273 | 10003291 | 0 | 107.9 | Curative (C) | 2015-04-08 | 2015-04-08 | TRASTUZUMAB | N | N | 10382831 | ECF |
| 10005274 | 10003292 | 1.66 | null | Neo-adjuvant (N) | 2018-07-22 | 2018-08-05 | CAPECITABINE + CISPLATIN + Trastuzumab | N | N | 10386958 | CETUXIMAB + RT |
| 10005275 | 10003293 | 1.76 | null | null | 2018-06-16 | 2018-06-17 | CETUXIMAB + RT | 2 | N | 10398472 | CETUXIMAB + IRINOTECAN + MDG |
| 10005276 | 10003294 | 1.71 | 59 | Palliative (P) | 2015-12-05 | 2016-01-05 | Cytarabine low (10to20mg/m2) IV/SC | 2 | null | 10398801 | CAPECITABINE + IRINOTECAN |
| 10005277 | 10003295 | 1.71 | 79.4 | Curative (C) | 2017-06-29 | 2017-07-05 | Pazopanib | 02 | N | 10398954 | TAC + TRASTUZUMAB |
| 10005278 | 10003296 | 1.7 | 76 | Palliative (P) | null | 2019-01-07 | CISPLATIN + FLUOROURACIL | 2 | N | 10399056 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005279 | 10003297 | 1.74 | 50 | Palliative (P) | 2018-05-02 | 2018-05-08 | Folfirinox | N | N | 10400042 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10005280 | 10003298 | null | null | Palliative (P) | 2017-08-22 | 2017-09-19 | IBRUTINIB | 1 | N | 10400601 | FLUOROURACIL + RT |
| 10005281 | 10006832 | 1.76 | 0 | Palliative (P) | 2018-08-31 | 2018-09-22 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 10400809 | GEFITINIB |
| 10005282 | 10003299 | 1.78 | 92.1 | Curative (C) | 2018-09-08 | 2018-09-15 | Cape+Cisplatin+Trastuzumab Load | 2 | N | 10401075 | LOMUSTINE |
| 10005283 | 10003299 | null | null | Disease modification (D) | 2011-09-19 | 2016-10-18 | TEMOZOLOMIDE | 02 | N | 10401075 | VINCRISTINE |
| 10005284 | 10003299 | 1.67 | 0 | Palliative (P) | 2019-05-27 | 2019-06-04 | Sorafenib | N | N | 10401075 | NIVOLUMAB |
| 10005285 | 10003299 | 1.69 | 112 | Palliative (P) | 2016-05-05 | 2016-05-17 | Fluorouracil + Folinic + RT Bossett | 1 | Y | 10401075 | GEFITINIB |
| 10005286 | 10003300 | null | 75 | null | 2017-02-03 | 2017-02-03 | Cisplatin +Fluorouracil (3 wk) | 2 | N | 10403803 | CARBOPLATIN + RT |
| 10005287 | 10003301 | 1.72 | null | Curative (C) | 2019-12-25 | 2019-12-25 | Lomustine | 2 | N | 10414364 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005288 | 10003302 | 1.62 | 106 | Palliative (P) | 2017-06-30 | 2017-06-30 | Dacarbazine | N | N | 10414586 | GEMCITABINE + NAB-PACLITAXEL |
| 10005289 | 10003303 | 1.68 | 64.6 | Curative (C) | 2017-02-22 | 2017-02-22 | Doxorubicin chemoembolisation | N | N | 10414661 | RAVVA TRIAL |
| 10005290 | 10003303 | 1.88 | 0 | null | 2018-12-30 | 2019-01-14 | PERM Trial | N | Y | 10414661 | BORTEZOMIB + THALIDOMIDE |
| 10005291 | 10003303 | null | 93 | Not known (9) | 2019-05-14 | 2019-05-23 | MITOMYCIN | 02 | N | 10414661 | FCR |
| 10005292 | 10003304 | null | 98.7 | Curative (C) | 2018-06-13 | 2018-07-05 | DABRAFENIB | Y | N | 10415563 | CISPLATIN + FLUOROURACIL |
| 10005293 | 10003305 | 1.71 | 82.8 | Palliative (P) | 2019-03-07 | 2019-03-08 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10415645 | CVP R + ETOPOSIDE |
| 10005294 | 10003306 | null | 105.1 | Curative (C) | 2019-02-07 | 2019-02-22 | CYTARABINE | N | N | 10415778 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 10005295 | 10003307 | 1.79 | 70.2 | Palliative (P) | 2018-05-28 | 2018-06-01 | Pazopanib | N | N | 10415858 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005296 | 10003308 | 0 | 55.8 | Palliative (P) | 2018-04-30 | 2018-05-14 | Pazopanib | N | N | 10415980 | PATHOS TRIAL |
| 10005297 | 10003309 | 1.8 | 78.5 | Palliative (P) | 2015-10-21 | 2015-11-02 | CISPLATIN + FLUOROURACIL | N | N | 10416168 | VEDEX |
| 10005298 | 10003309 | 1.55 | 79.8 | Palliative (P) | 2018-04-07 | 2018-05-05 | Trastuzumab Subcutaneous | N | Y | 10416168 | PAZOPANIB |
| 10005299 | 10003309 | 0 | 61 | Curative (C) | 2017-07-04 | 2017-08-09 | BORTEZOMIB + THALIDOMIDE | N | N | 10416168 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005300 | 10003310 | 1.85 | null | Adjuvant (A) | 2017-07-23 | 2017-07-23 | Sorafenib | N | N | 10417434 | HCX |
| 10005301 | 10003310 | 1.65 | 49.4 | Palliative (P) | 2018-09-01 | 2018-09-02 | Doxorubicin + Olaratumab | N | N | 10417434 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005302 | 10003311 | 1.54 | 73 | Curative (C) | 2015-02-05 | 2015-02-16 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | 02 | N | 10418040 | LANREOTIDE |
| 10005303 | 10003311 | 1.72 | 90.5 | Curative (C) | 2016-06-07 | 2016-06-07 | BORTEZOMIB + THALIDOMIDE | N | N | 10418040 | CHLVPP |
| 10005304 | 10003312 | null | 0 | Palliative (P) | 2019-01-18 | 2019-01-18 | Sunitinib | N | N | 10418630 | ECF |
| 10005305 | 10006838 | null | null | Disease modification (D) | 2017-07-27 | 2017-08-01 | CLADRIBINE | N | null | 10418698 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10005306 | 10003313 | 1.57 | 60 | Palliative (P) | 2019-02-08 | 2019-02-08 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | 02 | N | 10418794 | CYCLOPHOSPHAMIDE + RITUXIMAB |